{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:13:56Z","timestamp":1792016036273,"version":"4.4.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.ijid.2023.11.013","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T12:01:34Z","timestamp":1701172894000},"page":"124-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["Use of elexacaftor\/tezacaftor\/ivacaftor leads to changes in detection frequencies of Staphylococcus aureus and Pseudomonas aeruginosa dependent on age and lung function in people with cystic fibrosis"],"prefix":"10.1016","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9582-1025","authenticated-orcid":false,"given":"Anna-Maria","family":"Dittrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Sieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7146-6997","authenticated-orcid":false,"given":"Lutz","family":"Naehrlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Burkhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Hafkemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2566-8758","authenticated-orcid":false,"given":"Burkhard","family":"T\u00fcmmler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2023.11.013_bib0001","article-title":"Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis","volume":"11","author":"Smith","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijid.2023.11.013_bib0002","series-title":"German Cystic Fibrosis Registry","author":"Naehrlich","year":"2021"},{"key":"10.1016\/j.ijid.2023.11.013_bib0003","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1513\/AnnalsATS.201806-368AW","article-title":"Emerging concepts and therapies for Mucoobstructive lung disease","volume":"15","author":"Mall","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.ijid.2023.11.013_bib0004","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02153-2022","article-title":"Longitudinal effects of Elexacaftor\/Tezacaftor\/Ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis","volume":"62","author":"Schaupp","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijid.2023.11.013_bib0005","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jcf.2021.03.008","article-title":"Real-world use of ivacaftor in Canada: a retrospective analysis using the Canadian Cystic Fibrosis Registry","volume":"20","author":"Kawala","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.ijid.2023.11.013_bib0006","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1513\/AnnalsATS.201902-122OC","article-title":"Ivacaftor is associated with reduced lung infection by key cystic fibrosis pathogens. A cohort study using national registry data","volume":"16","author":"Frost","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.ijid.2023.11.013_bib0007","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1016\/S1569-1993(19)30549-1","article-title":"P256 The effect of ivacaftor on adult cystic fibrosis patients at the Royal Hospital in Oman","volume":"18","author":"Al-Rashdi","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.ijid.2023.11.013_bib0008","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.rmed.2017.08.026","article-title":"Ivacaftor for the p.Ser549Arg (S549R) gating mutation \u2013 The Israeli experience","volume":"131","author":"Dagan","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.ijid.2023.11.013_bib0009","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/jcpt.12616","article-title":"Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G\u203aA (G551D)-CFTR treated with ivacaftor-Changes in microbiological parameters","volume":"43","author":"Millar","year":"2018","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.ijid.2023.11.013_bib0010","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1513\/AnnalsATS.201907-493OC","article-title":"Changes in airway microbiome and inflammation with ivacaftor treatment in patients with cystic fibrosis and the G551D mutation","volume":"17","author":"Harris","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.ijid.2023.11.013_bib0011","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.03148-21","article-title":"Combining ivacaftor and intensive antibiotics achieves limited clearance of cystic fibrosis infections","volume":"12","author":"Durfey","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.ijid.2023.11.013_bib0012","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1164\/rccm.202110-2249OC","article-title":"Effects of Elexacaftor\/Tezacaftor\/Ivacaftor therapy on CFTR function in patients with cystic fibrosis and one or two F508del alleles","volume":"205","author":"Graeber","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijid.2023.11.013_bib0013","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","article-title":"Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study","volume":"22","author":"Bower","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.ijid.2023.11.013_bib0014","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/ppul.26362","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on bacterial cultures from people with cystic fibrosis","volume":"58","author":"Beck","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.ijid.2023.11.013_bib0015","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jcf.2021.02.003","article-title":"PROMISE: working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy","volume":"20","author":"Nichols","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.ijid.2023.11.013_bib0016","doi-asserted-by":"crossref","first-page":"e15756","DOI":"10.1016\/j.heliyon.2023.e15756","article-title":"Elexacaftor - Tezacaftor - ivacaftor treatment improves systemic infection parameters and Pseudomonas aeruginosa colonization rate in patients with cystic fibrosis a monocentric observational study","volume":"9","author":"Schnell","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.ijid.2023.11.013_bib0017","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1164\/rccm.202210-1938LE","article-title":"Moving the dial on airway inflammation in response to Trikafta in adolescents with cystic fibrosis","volume":"207","author":"Lepissier","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijid.2023.11.013_bib0018","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/ppul.26261","article-title":"Impact of elexacaftor-tezacaftor-ivacaftor on bacterial colonization and inflammatory responses in cystic fibrosis","volume":"58","author":"Sheikh","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.ijid.2023.11.013_bib0019","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1136\/thorax-2022-219943","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on airway and systemic inflammation in cystic fibrosis","volume":"78","author":"Casey","year":"2023","journal-title":"Thorax"},{"key":"10.1016\/j.ijid.2023.11.013_bib0020","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167957","article-title":"Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist","volume":"133","author":"Nichols","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijid.2023.11.013_bib0021","series-title":"MiQ24: Atemwegsinfektionen bei Mukoviszidose","author":"Hogardt","year":"2019"},{"key":"10.1016\/j.ijid.2023.11.013_bib0022","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01454-22","article-title":"Impact of Elexacaftor\/Tezacaftor\/Ivacaftor therapy on the cystic fibrosis airway microbial metagenome","volume":"10","author":"Pallenberg","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.ijid.2023.11.013_bib0023","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jcf.2021.08.009","article-title":"Longitudinal changes and regional variation of incident infection rates at cystic fibrosis centers, United States 2010\u20132016","volume":"21","author":"Muhlebach","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.ijid.2023.11.013_bib0024","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1034\/j.1399-3003.2000.16d30.x","article-title":"Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus","volume":"16","author":"D\u00f6ring","year":"2000","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijid.2023.11.013_bib0025","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1164\/rccm.201606-1107CI","article-title":"Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST-CF). Early lung disease in infants and preschool children with cystic fibrosis. What have we learned and what should we do about it?","volume":"195","author":"Ranganathan","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijid.2023.11.013_bib0026","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1172\/JCI0213870","article-title":"Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients","volume":"109","author":"Worlitzsch","year":"2002","journal-title":"J Clin Invest"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971223007749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971223007749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T04:01:18Z","timestamp":1717300878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971223007749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":26,"alternative-id":["S1201971223007749"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2023.11.013","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of elexacaftor\/tezacaftor\/ivacaftor leads to changes in detection frequencies of Staphylococcus aureus and Pseudomonas aeruginosa dependent on age and lung function in people with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2023.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}